Aethlon Medical has enrolled the first patient in its Australian clinical trial evaluating the safety, feasibility, and ...

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Keytruda (pembrolizumab ... or appropriate for all patients or all specific uses.

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

Earlier this year, Summit Therapeutics and Akeso unveiled new data on their PD-1/VEGF-A bispecific drug, ivonescimab, showing ...

While some of the initial excitement around immunotherapies has waned, companies—particularly smaller biotechs—are developing ...

Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

Aethlon Medical (AEMD) announced enrollment of the first patient in its Australian safety, feasibility and dose-finding clinical trial of the ...

"By 2024, the market is projected to reach a staggering US$597.00bn worldwide. Among these markets, Medical Devices are expected to dominate, with a projected market volume of US$508.00bn by 2024.

Combination Dose Escalation Tumor Response: Encouraging preliminary signs of anti-tumor activity were observed with MDNA11 in combination with KEYTRUDA in dose escalation cohorts 1 and 2. Among 5 ...

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced enrollment of the first ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...